The report examines various patient scenarios to illustrate factors contributing to patients’ out-of-pocket costs, such as cancer type, access to treatment options, and insurance coverage. Additionally, the report presents public-policy recommendations for making cancer treatments more affordable for patients, survivors, and the healthcare system as a whole. For example, ACS-CAN encourages policymakers to explore ways to incentivize the use of biosimilars through reducing or eliminating cost sharing for patients.